Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Kidney Int. 2017 Dec 19;93(4):842–854. doi: 10.1016/j.kint.2017.09.029

Figure 4. Systemic administration of ELP-VEGF improved angiogenic signaling and stimulated progenitor cells in the stenotic kidney.

Figure 4

Figure 4

4A) Representative renal protein expression (2 bands per group) and quantification of vascular endothelial growth factor (VEGF) and its receptor Flk-1 (top), hypoxia induced factor (HIF)-1α, hepatocyte growth factor (HGF), and HGF receptor cMet (middle), and total and phosphorylated (p)-akt, ERK ½, and endothelial nitric oxide synthase (eNOS, bottom) in normal, RVD and RVD+ELP-VEGF stenotic kidneys. 4B) Representative pictures of immunoreactivity against Oct-4 (40x), stromal-derived factor (SDF)-1 (20x), and CD-34 (20x) and quantification in normal, RVD and RVD+ELP-VEGF stenotic kidneys. * p<0.05 vs. Normal; † p<0.05 vs. RVD; #p>0.1 vs. RVD.